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Introduction
In eukaryotic cells, messenger precursor molecules must undergo 
a series of maturation events that include 5′ capping, splicing, 
3′ end cleavage, and polyadenylation. During processing, nascent 
mRNA assembles together with RNA binding proteins into ribo-
nucleoprotein particles (mRNPs; Aguilera, 2005; Moore, 2005). 
Mature particles are exported to the cytoplasm and several lines 
of evidence indicate that mRNPs move from the sites of tran-
scription to the nuclear pores by random Brownian motion. As dif-
fusion cannot be regulated, traffi  c control of newly synthesized 
mRNA molecules is thought to rely on retention at dedicated sites 
within the nucleus (Gorski et al., 2006). According to the current 
view, any failure compromising the integrity of an mRNA may 
cause its retention in the nucleus and trigger its degradation. There 
is evidence suggesting that such a surveillance mechanism oper-
ates in close proximity to the gene template (Jensen et al., 2003) 
and, at least in yeast, at the nuclear pore (Galy et al., 2004).
A key connection between transcription and mRNP bio-
genesis is provided by the C-terminal domain (CTD) of the larg-
est subunit of RNA polymerase II (RNA Pol II LS), which binds 
several proteins essential for pre-mRNA processing (Bentley, 
2005). The CTD of RNA Pol II LS is highly conserved, increas-
ing in length and diversifying in structure with the complexity of 
organisms (Stiller and Hall, 2002). Contrasting with yeast, which 
contains 26 repeats of a conserved heptapeptide with the consen-
sus sequence YSPTSPS, the mammalian CTD has 52 repeats, of 
which 21 obey the conserved consensus while the remainder dis-
play a variety of substitutions. Most of these nonconsensus repeats 
are located in the C-terminal part of the CTD (heptads 27–52; 
Fig. 1 A), and the last repeat (CTD52) is essential for cell 
viability and Pol II stability (Chapman et al., 2004). At the 
very C terminus, the mammalian CTD further comprises a spe-
cifi  c 10-amino acid motif. CTD deletion analysis has shown that 
heptad repeats 1–15 or 1–25 support capping but not splicing or 
3′ end formation, whereas heptads 27–52 plus the C-terminal 10 
residues can support effi  cient capping, splicing, and 3′ end forma-
tion (Fong and Bentley, 2001). More recent studies have demon-
strated that scrambling the 10 residues that lie C-terminal of 
heptad 52 impairs effi  cient release of RNA from the site of tran-
scription (Bird et al., 2005). However, this mutation also reduces 
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splicing and 3′ end cleavage (Fong et al., 2003), arguing that the 
CTD requirement for RNA release may be a consequence of its 
role in promoting pre-mRNA processing.
To further investigate the role of the CTD in transcript 
release, we generated murine erythroleukemia (MEL) cell lines 
that express α-amanitin–resistant RNA Pol II LS with either 
full-length or truncated forms of the CTD. Our results reveal 
that deleting 21 C-terminal heptads of the CTD causes transcript 
retention at the site of transcription but without inhibiting splic-
ing or 3′ end formation. This implies a previously unsuspected 
involvement of the CTD in mRNP maturation events that occur 
after splicing, cleavage, and polyadenylation have taken place.
Results and discussion
Deletion of the CTD to 5 heptads abolishes 
LCR-dependent transcriptional activation 
of the Hbb1 gene
MEL cells were stably transfected with an α-amanitin–resistant 
form of the RNA polymerase II largest subunit (RNA Pol II LS; 
Bartolomei and Corden, 1987) containing either wild-type or de-
letion mutants of the CTD with 31 (∆31) or 5 heptad repeats (∆5) 
(Fig. 1 A; Bartolomei et al., 1988; Gerber et al., 1995). Each of 
these plasmids was cotransfected with a second plasmid contain-
ing the human β-globin gene (HBB) micro-locus control region 
(βLCR) and a puromycin resistance gene (Collis et al., 1990; 
Millevoi et al., 2002). Given the tendency of multiple copies 
of plasmid transgenes to co-integrate as tandem arrays, we rea-
soned that this cotransfection procedure should, in many cases, 
result in the positioning of the βLCR-bearing plasmid upstream 
of the α-amanitin–resistant RNA Pol II LS constructs. As the 
βLCR is able to activate heterologous, nonerythroid promoters 
(Blom van Assendelft et al., 1989; Collis et al., 1990) with the 
minimum requirements being a CAAT and CACCA or GC-rich 
(e.g., Sp1) elements (Antoniou and Grosveld, 1990; and unpub-
lished data), this confi  guration should confer erythroid-specifi  c 
induced transcription on the human cytomegalovirus (CMV) 
promoter linked to the α-amanitin–resistant RNA Pol II LS cas-
settes. Stably transfected clones were selected with puromycin 
and screened by an S1-nuclease protection assay for expression 
of the transfected RNA Pol II LS gene. We selected clones that 
showed low levels of exogenous, transgene-derived α-amanitin–
resistant RNA Pol II LS expression in preinduced cells and high 
levels after 4 d of differentiation. Expression of the exogenous 
RNA Pol II LS was confi  rmed by Western blotting analysis with 
an antibody that recognizes the haemagglutinin (HA) epitope 
(Fig. 1 B), as previously described (Custódio et al., 2006).
We next confi  rmed that the exogenous RNA Pol II LS was 
functional. The endogenous RNA Pol II LS is degraded upon 
binding of α-amanitin (Nguyen et al., 1996), but the exogenous 
transgene-derived protein is resistant due to a single amino acid 
substitution that decreases its affi  nity for the toxin (Bartolomei 
and Corden, 1987). We therefore determined the ability of the dif-
ferent clones to transcribe endogenous murine β
major-globin gene 
(Hbb1) in the presence of α-amanitin. After 17 h of α-amanitin 
treatment, S1-nuclease protection assays revealed no signal for 
Hbb1 pre-mRNA in untransfected MEL C88 cells, confi  rming 
that transcription by the endogenous RNA Pol II was abolished 
(Fig. 1 C, lane C88 +). In marked contrast, Hbb1 pre-mRNA 
was present in clones expressing the α-amanitin–resistant forms 
of RNA Pol II LS containing either the full-length CTD (Fig. 1 C, 
lane wt +) or the ∆31 truncation (Fig. 1 C, lane ∆31 +), but 
not the ∆5 variant (Fig. 1 C, lane ∆5 +). The fi  nding that none 
of the clones expressing RNA Pol II ∆5 were able to support 
transcription of Hbb1 was surprising, taking into account that 
this mutant was previously shown to transcribe HBB under con-
trol of the SV40 promoter (McCracken et al., 1997b) and a rat 
homeobox reporter gene stably integrated into the genome of 
Figure 1.  A large deletion of the CTD abolishes LCR-dependent Hbb1 
transcriptional activation. (A) Schematic representation of the RNA Pol II 
LS constructs. (B) Western blotting analysis. Total protein extracts were 
prepared from untransfected MEL C88 and from cells transfected with 
the indicated constructs, both before (UI) and after 4 d of erythroid dif-
ferentiation (4d). The blot was incubated with antibodies anti-HA and 
anti-tubulin. (C) S1-nuclease protection assay. MEL C88 cells and cells 
transfected with the indicated constructs were induced for 4 d either with 
(+) or without (−) treatment with α-amanitin for 17 h. Hbb1 expression 
was analyzed with a probe that produces protected fragments of 336 and 
96 nt for the pre-mRNA and mRNA, respectively. Due to its long half-life, 
high levels of mRNA synthesized before treatment with α-amanitin persist 
in the treated cells.A NEW ROLE FOR THE CTD IN MRNA BIOGENESIS • CUSTÓDIO ET AL. 201
HeLa cells (Misteli and Spector, 1999). Additional studies in-
dicated that the truncated variant of the CTD with only 5 heptad 
repeats did not affect TATA-box–mediated transcription (Gerber 
et al., 1995; McCracken et al., 1997b). However, this same 
form of the CTD in yeast and humans abolished activator-
dependent induction of transcription of specifi  c genes (Allison 
and Ingles, 1989; Gerber et al., 1995; Meininghaus and Eick, 
1999). Furthermore, nuclear run-on experiments in mammalian 
cells suggested a global defect in transcription of endogenous 
genes (Meininghaus et al., 2000). Because endogenous murine 
Hbb1 is under control of the LCR (Collis et al., 1990), our ob-
servation that RNA Pol II ∆5 fails to support LCR-dependent 
transcription is consistent with previous data indicating a require-
ment of the CTD for enhancer-driven transcription (Allison and 
Ingles, 1989; Gerber et al., 1995; Meininghaus and Eick, 1999).
Deletion of the CTD to 31 heptads 
causes mRNA retention at the site 
of transcription
Having selected MEL cell clones that express functional 
α-amanitin–resistant wild-type or ∆31 RNA Pol II LS, we next 
super-transfected these cells with an HBB transgene that was 
either wild type (βWT) or a mutant variant possessing a GT to AC 
mutation at the 5′ splice site of the second intron (βSM) (Fig. 2 A). 
As this mutation inhibits splicing and causes retention of the RNA 
at the transcription site (Custódio et al., 1999), we were inter-
ested in determining whether the CTD is involved in recognition 
of the resulting aberrantly processed βSM pre-mRNA. Cells 
were induced for 3 d and analyzed by FISH. As previously 
described (Custódio et al., 1999), the transcription site of the 
βWT or βSM transgene is detected as a focus in the nucleus 
(Fig. 2 B). The wild-type mRNA is exported from the nucleus 
and accumulates in the cytoplasm (Fig. 2 B, a), in contrast 
to the mutant RNA, which is not detected in the cytoplasm 
(Fig. 2 B, e). Treatment of cells devoid of exogenous transgene-
derived RNA Pol II with α-amanitin results in the disappearance 
of nuclear foci (Fig. 2 B, b and f). Contrastingly, nuclear foci 
remain clearly visible in cells transfected with α-amanitin–
resistant forms of RNA Pol II LS (Fig. 2 B, c, d, g, and h).
We have previously shown that treating MEL cells with 
the transcription inhibitor actinomycin D for a short period of 
time (5–15 min) causes a dramatic, rapid reduction in the relative 
number of cells that contain a detectable nuclear focus of βWT 
transcripts within the nucleus, whereas the percentage of cells 
harboring βSM RNA foci remained largely unaltered, suggest-
ing that these mutant RNAs were not being released from the site 
of transcription (Custódio et al., 1999). We therefore performed 
the same assay using cells that express the α-amanitin–resistant 
forms of RNA Pol II LS in an effort to gain insight into the pos-
sible role of the CTD in the process of mRNA release from the 
transcription site. The results show that actinomycin D treatment 
of cells expressing either endogenous RNA Pol II LS or the 
α-amanitin–resistant full-length CTD transgene product resulted 
in a signifi  cant decrease in the percentage of cells with βWT 
Figure 2.  Visualization of nascent RNA transcribed by transgene-derived RNA Pol II LS. (A) Schematic representation of wild-type (βWT) and splice mutant 
(βSM) human β-globin (HBB) constructs. Exons in the HBB gene are numerated (I, II, III). The probe used for FISH is complementary to exon I, intron I, and 205 nt 
of exon II. (B) Detection by FISH of βWT and splice mutant βSM RNA synthesized by either endogenous RNA Pol II or transgene-derived constructs, as indicated. 
All cells were induced for 3 d and either treated or untreated with α-amanitin as indicated. Dashed lines indicate the periphery of the nucleus. Bar, 10 μm.JCB • VOLUME 179 • NUMBER 2 • 2007  202
transcription foci (Fig. 3 A, a–d; and Fig. 3 C, a), as well as in 
the intensity of the remaining signal (Fig. 3 D). However, when 
transcription is dependent on the α-amanitin–resistant RNA 
Pol II LS containing the truncated ∆31 CTD, actinomycin D treat-
ment does not cause any signifi  cant reduction in the percentage 
of cells with a visible focus (Fig. 3 A, e, f; and Fig. 3 C, a) or 
in the mean fluorescence intensity of each focus (Fig. 3 D). 
We therefore conclude that the transcripts are not being effi  ciently 
released. Parallel experiments performed with cells expressing 
the mutant HBB transgene showed that treatment with actino-
mycin D causes no signifi  cant change in the percentage of cells 
with a visible nuclear focus of βSM RNA (Fig. 3 B), regardless 
of whether this gene is transcribed by full-length (Fig. 3 B c, d; 
and Fig. 3 C, b) or truncated (Fig. 3 B, e, f; and Fig. 3 C, b) CTD 
versions of α-amanitin–resistant RNA Pol II LS. Thus, reducing 
the CTD to 31 heptad repeats is suffi  cient to prevent release of 
RNA transcribed from a normal gene while it does not interfere 
with the ability to retain transcripts derived from a gene with a 
severe splice mutation.
RNA transcribed by RNA Pol II LS 𝖫31 is 
spliced, cleaved, and polyadenylated
Previous studies have shown that deletion mutants of the CTD 
induce defects in splicing and 3′ end cleavage (McCracken et al., 
1997b; Fong and Bentley, 2001; Fong et al., 2003). We therefore 
analyzed wild-type HBB (βWT) transcripts produced by endog-
enous or exogenous transgene RNA Pol II LS by RNase pro-
tection assays to monitor splicing of introns 1 and 2 as well 
as cleavage at the poly(A) addition site (Fig. 4 A). As expected, 
no signal for unspliced (US; Fig. 4 B, lane 2) and uncleaved 
(UC; Fig. 4 B, lane 4) HBB RNA was detected after inactivation 
of the endogenous RNA Pol II LS with α-amanitin (Fig. 4 B).
However, bands corresponding to spliced (SP) and cleaved (CL) 
RNA were still present, most probably due to the long half-life 
of HBB mRNA.
To avoid complications caused by the presence of HBB 
mRNA synthesized by the endogenous RNA Pol II LS and 
which had accumulated before α-amanitin treatment, cells were 
exposed to this toxin immediately after the fi  rst day of induced 
erythroid differentiation. In MEL cells containing the βWT 
transgene and which rely exclusively on the endogenous RNA 
Pol II for transcription, this resulted in massive cell death, while 
there was survival of cells transfected with the α-amanitin–
resistant forms of RNA Pol II LS. In these cells, after inactivation 
of the endogenous RNA Pol II LS, bands corresponding to both 
unspliced and spliced (Fig. 4 C, lanes 2 and 3) as well as un-
cleaved and cleaved (Fig. 4 C, lanes 5 and 6) products were 
clearly detected. In a control experiment, we analyzed RNA 
extracted from MEL cells containing the βWT transgene that 
had undergone the same period (3 d) of differentiation but not 
exposed to α-amanitin (Fig. 4 C, lanes 1 and 4). The results 
(Fig. 4 D) revealed no substantial reduction in the percentage of 
spliced and 3′ cleaved βWT mRNA transcribed by RNA Pol II 
LS ∆31 compared with that synthesized by either RNA Pol II LS 
wild type or endogenous RNA Pol II. We further observed that 
poly(A) tail length of HBB mRNA was similar in transcripts syn-
thesized by either endogenous RNA Pol II RNA (Fig. 4 E, lane 2), 
RNA Pol II LS wild type (Fig. 4 E, lane 3), or Pol II LS ∆31 
(Fig. 4 E, lane 4). Thus, a CTD with heptad repeats 1–23, 
36–38, and 48–52 followed by the unique terminal 10-amino 
acid motif is suffi   cient to support effi   cient pre-mRNA pro-
cessing, as predicted from previous studies (Fong et al., 2003; 
Rosonina and Blencowe, 2004).
Collectively, our data reveal that βWT transgene mRNA 
synthesized by the RNA Pol II ∆31 mutant is effi  ciently spliced, 
cleaved, and polyadenylated and yet remains in close vicinity 
to the gene after inhibition of transcription. This strongly 
suggests that the CTD is required for mRNA release from the 
site of transcription in a manner independent of splicing and 
3′ formation. A possible splicing-independent involvement of 
the CTD in RNA release was also noted by Bentley and col-
leagues, who observed that intron-less pre-mRNA synthesized 
by a terminal 10-amino acid motif mutant CTD remained at 
the site of transcription, whereas synthesis by a wild-type CTD 
resulted in RNA release (Bird et al., 2005). However, the use of 
an intron-less reporter gene in these studies precluded defi  nitive 
conclusions to be drawn.
EJC proteins and the PM/Scl-100 
exosome subunit are recruited 
to nascent transcripts synthesized 
by CTD mutant RNA Pol II
We have previously shown that exon junction complex (EJC) 
proteins and core spliceosome components (U snRNPs) accu-
mulate on nascent wild-type HBB transcripts, but fail to asso-
ciate with mutant transcripts that are not released from the 
transcription site (Custódio et al., 2004). To assess if the pres-
ence of truncation mutants of the RNA Pol II LS CTD affected 
this process, we conducted double-labeling (FISH plus immuno-
cytochemical staining) of MEL cells that contained the βWT 
transgene transcribed by either endogenous or exogenous RNA 
Pol II (full-length or the ∆31 CTD mutant) after treatment with 
α-amanitin as before (Fig. 5). We used a probe to detect βWT 
transcripts and antibodies to detect snRNP Sm proteins (Fig. 5, 
a–c), and EJC components SRm160 (Fig. 5, e–g) and Aly/REF 
(Fig. 5, i–k). Using a previously described quantitative single-cell 
assay (Misteli et al., 1998; Mabon and Misteli, 2005), we detected 
all three proteins recruited to nascent transcripts irrespective 
of CTD length (Fig. 5, a′–k′ and d, h, and l). Moreover, we ob-
served that colocalization of EJC proteins with transcripts syn-
thesized by RNA Pol II LS ∆31 CTD persists after inhibi  tion of 
transcription by actinomycin D, which adds additional evidence 
that RNA transcribed by RNA Pol II harboring a truncated ∆31 
CTD and retained at the transcription site is normally spliced. 
In the yeast Saccharomyces cerevisiae, retention of de-
fective mRNA at the site of transcription requires Rrp6p and 
other components of the nuclear exosome, suggesting that this 
complex is part of a quality control checkpoint that monitors for 
correct processing of pre-mRNA (Hilleren et al., 2001; Jensen 
et al., 2001; Libri et al., 2002; Dunn et al., 2005). We therefore 
investigated whether the mammalian orthologue of Rrp6p asso-
ciates with nascent βWT transcripts by immunofl  uorescence 
using a specifi  c antibody (Brouwer et al., 2001). This protein 
was readily detectable throughout the nucleoplasm with a high A NEW ROLE FOR THE CTD IN MRNA BIOGENESIS • CUSTÓDIO ET AL. 203
Figure 3. The  CTD  𝖫31 mutation causes mRNA retention at the site of transcription. RNA transcribed from βWT (A) and splice mutant βSM (B) transgenes 
was visualized by FISH. Transcription was by endogenous or exogenous RNA Pol II LS, as indicated. Treatment with actinomycin D was for 15 min. Bar, 
10 μm. (C) The proportion of cells with a nuclear RNA focus, before and after actinomycin D. A total of 500–700 cells were counted in each experiment. 
Results are presented as means ± SD for at least three independent experiments; P values relative to nontreated cells (t test) are indicated. Due to a combi-
nation of the asynchronous nature of the cell cultures and position-effect variegation, not all cells contain a visible nuclear focus. As the fraction of cells with 
a nuclear focus varies between cell lines, the interpretation of the data relies on the comparison of the fraction of cells from the same line that contain a 
nuclear focus before and after treatment with actinomycin D. (D) Mean ﬂ  uorescence intensity (arbitrary units, AU) of the nuclear βWT RNA focus, before 
and after actinomycin D. A total of 100 nuclear RNA foci were quantiﬁ  ed in each experiment. Results are presented as mean ﬂ  uorescence intensity ± SE 
for two independent experiments; P values relative to nontreated cells (t test) are indicated.JCB • VOLUME 179 • NUMBER 2 • 2007  204
Figure 4. The  CTD  𝖫31 mutant supports splicing, cleavage, and polyadenylation. (A) Schematic representation of the RNase protection assay probes. 
(B) Nuclear RNA (2 μg) from MEL cells transfected with βWT (Fig. 2) induced to differentiate for 3 d and untreated (−) or treated (+) with α-amanitin for 19 h 
were analyzed by an RNase protection assay using the indicated probes; intron I unspliced (US I), intron II unspliced (US II), intron I spliced (SP I), intron II 
spliced (SP II), uncleaved (UC), and cleaved (CL). (C) Nuclear RNA fractions from cells transcribing the βWT transgene either by endogenous Pol II LS 
(endog.; 2.5 μg) or by exogenous RNA Pol II LS wild-type (wt; 5 μg) or RNA Pol II LS ∆31 (∆31; 5 μg) that were induced to differentiate for 3 d and untreated 
(−) or treated (+) with α-amanitin for 2 d were analyzed using the same probes. (D) Quantiﬁ  cation of splicing and cleavage efﬁ  ciencies. The amount of un-
spliced (US), spliced (SP), uncleaved (UC), and cleaved (CL) RNA from three independent experiments was determined from PhosphorImager data cor-
rected for [
32P]U content of the RNase-protected fragment. Percentages of splicing and cleavage were calculated by dividing the value of spliced or cleaved 
product by the sum of the values of spliced and unspliced products or cleaved and uncleaved products, respectively. (E) Poly(A) tail length analysis of HBB 
transcripts. The diagram on the left illustrates the PCR-ampliﬁ  ed products. Primers were designed to amplify a 254-nt product if the mRNA is not polyadenyl-
ated and any length over 254 nt is contributed by the poly(A) tail. On the right, an ethidium bromide–stained agarose gel with the products obtained from 
cells transcribing the βWT transgene either by endogenous Pol II LS (endog.; lane 2) or by exogenous RNA Pol II LS wild-type (wt; lane 3) or RNA Pol II LS 
∆31 (∆31; lanes 4 and 5) that were induced to differentiate for 3 d and untreated (−) or treated (+) with α-amanitin for 2 d. RNA from lane 5 was treated 
with RNase H in the presence of oligo dT12–18. Lanes 1 and 6 contain a 50-bp ladder. Similar results were obtained in two independent experiments.A NEW ROLE FOR THE CTD IN MRNA BIOGENESIS • CUSTÓDIO ET AL. 205
Figure 5.  EJC proteins and the exosome subunit PM/Scl-100 are recruited to the HBB transcription site. MEL cells were induced for 3 d and treated with 
α-amanitin. The βWT transgene (Fig. 2) was transcribed by endogenous RNA Pol II (a, e, i, and m), RNA Pol II LS wt (b, f, j, and n), or RNA Pol II LS ∆31 
(c, g, k, and o). Cells were double-labeled for HBB RNA (red staining) and for protein (green staining) using the indicated antibodies. Relative ﬂ  uorescence 
intensity (in arbitrary units) was measured along a line across the βWT RNA focus. We considered a positive recruitment when the intensity of the protein 
signal at the focus was more than twofold higher than the global nucleoplasmic signal (Mabon and Misteli, 2005). Representative results are shown for the 
indicated proteins. The proportion of cells exhibiting recruitment was quantiﬁ  ed. Values represent average from 45 transcription sites analyzed in two inde-
pendent experiments ± SD.JCB • VOLUME 179 • NUMBER 2 • 2007  206
concentration at the site of βWT transgene transcription (Fig. 5, 
m–o). Similar results were observed in cells that express exoge-
nous RNA Pol II LS with either a wild-type (Fig. 5, n, n′, and p) 
or truncated ∆31 (Fig. 5, o, o′, and p) CTD.
Collectively, these data indicate that recruitment of neither 
EJC proteins nor nuclear exosome Rrp6 class of proteins to nascent 
mRNA is suffi  cient for its release from the site of transcription.
Conclusions
Accumulation of nascent mRNA in close proximity to their 
transcription site is thought to represent a surveillance mecha-
nism that prevents defectively processed transcripts from enter-
ing the fl  ow to the cytoplasm (Saguez et al., 2005; Gorski et al., 
2006). A major player in cotranscriptional pre-mRNA matura-
tion is the CTD of RNA Pol II, which acts by facilitating spe-
cifi  c interactions between processing factors while the transcript 
is still attached to the polymerase (for review see Bentley, 2005). 
Previous work revealed that a mutation of the terminal 10-amino 
acid motif of the CTD inhibited splicing, 3′ end cleavage (Fong 
et al., 2003), and RNA release from the site of transcription 
(Bird et al., 2005). Based on these observations it was proposed 
that the CTD is required for transcript release as a consequence 
of its role in splicing and 3′ end cleavage (Bird et al., 2005). 
However, in this report we show that a partial truncation of the 
CTD (∆31) containing heptads 1–23, 36–38, and 48–52 includ-
ing the terminal 10-amino acid motif is suffi  cient to support 
transcription, splicing, 3′ end cleavage, and polyadenylation, 
but the newly synthesized mRNA fails to be effi  ciently released 
(Figs. 3 and 4). These novel observations imply that the CTD is 
involved in processes that control the release of transcripts by 
a mechanism independent from splicing and cleavage. Collec-
tively with previously reported data (Bird et al., 2005), our re-
sults further suggest that different segments of the CTD play 
distinct roles in pre-mRNA processing and mRNA release from 
the vicinity of the gene template.
Although the mechanism via which the RNA Pol II LS 
CTD is involved in the release of mRNA from the transcription 
site is unknown, we speculate that the ∆31 CTD truncation mu-
tant used in this study fails to bind and therefore recruit protein 
factors required to complete maturation of spliced and 3′ end 
cleaved/polyadenylated mRNA into export-competent mRNPs. 
We further propose that this defect in production of fully mature 
mRNA activates a quality control checkpoint or surveillance 
mechanism that prevents diffusion of mRNPs to the nuclear 
pores by tethering them near the gene template, with stalled 
mRNA being subsequently degraded by the exosome present at 
the transcription site. A prediction from this mechanistic model 
is that most mRNA transcribed by the ∆31 CTD mutant should 
not translate into protein. In good agreement with that predic-
tion is the observation that the ∆31 CTD mutation cannot sup-
port long-term cell viability (Meininghaus et al., 2000).
Materials and methods
MEL cell culture and stable transfections
The maintenance, induction of erythroid differentiation, and stable trans-
fection of the MEL cell line C88 were described elsewhere in detail 
(Antoniou, 1991). The cells were cotransfected as previously described 
(Custódio et al., 2006) with an α-amanitin–resistant RNA Pol II LS gene 
with either a full-length CTD (52 heptad repeats, wild type) or a CTD with 
31 (∆31) or 5 (∆5) repeats (Fig. 1 A; Bartolomei et al., 1988; Gerber et al., 
1995; plasmids provided by W. Schaffner, University of Zürich, Zürich, 
Switzerland) and a plasmid containing the βLCR (Collis et al., 1990) modi-
ﬁ  ed to carry a puromycin resistance gene under the control of a phospho-
glycerate kinase promoter (Millevoi et al., 2002). Before transfection the 
RNA Pol II LS wild-type plasmid was linearized with MluI, the ∆31 and ∆5 
plasmids were linearized with ClaI and the micro-βLCR plasmid was linear-
ized with PvuI. Stable transfected clones were obtained by culture in the 
presence of 2.5 μg/ml puromycin (Sigma-Aldrich). Clones selected for further 
studies were then super-transfected with either the wild-type (βWT) or 
mutant (βSM) HBB genes in the micro-βLCR expression vector (Fig. 2 A; 
Custódio et al., 1999) with stably transfected cells isolated in the presence 
of 800 μg/ml G418. The function of endogenous RNA Pol II LS was inhib-
ited by adding α-amanitin (Sigma-Aldrich) to the cell culture medium to a 
ﬁ  nal concentration of 2.5 μg/ml.
In situ hybridization and immunoﬂ  uorescence analysis
HBB transcripts were visualized by FISH (Custódio et al., 1999) and double 
labeling for RNA and protein was as previously described (Custódio et al., 
2004). The probe used for FISH was a 740-bp fragment of the human β-globin 
gene extending from the SnaBI site at −265 bp from the transcriptional 
start point to the BamHI site at +475 bp. The fragment was labeled by nick-
translation with either digoxigenin-11-dUTP (Roche) or Cy3-AP3-dUTP (GE 
Healthcare). The following primary antibodies were used for immunoﬂ  uores-
cence: rabbit polyclonal directed against SRm160 (1:500; Blencowe et al., 
1998; provided by B. Blencowe, University of Toronto, Ontario, Canada), 
mouse monoclonal directed against Aly/REF (1:100; clone 11G5; AbCam), 
human autoantiserum C45, speciﬁ   c for Sm proteins (1:75; provided by 
W. van Venrooij, University of Nijmegen, Nijmegen, Netherlands) and rab-
bit serum against PM/Scl-100 (1:75; provided by Ger Pruijn, University of 
Nijmegen). The secondary antibodies used were: AlexaFluor 488–conjugated 
goat anti–rabbit IgG (1:200; Jackson ImmunoResearch Laboratories, Inc.), 
AlexaFluor 488–conjugated goat anti–mouse IgG (1:200; Jackson Immuno-
Research Laboratories, Inc.), and FITC-conjugated donkey anti–human IgG 
(1:100; Jackson Immuno  Research Laboratories, Inc.).
Microscopy and image quantiﬁ  cation
Images were acquired on a laser scanning confocal microscope (LSM 510 
or LSM 510 META; Carl Zeiss MicroImaging, Inc.) using the PlanApochro-
mat 63×/1.4 objective. FITC and AlexaFluor 488 ﬂ  uorescence was de-
tected using the 488-nm line of the argon ion laser. Cy3 was excited with 
the 543-nm line of the helium-neon laser on the Zeiss LSM 510 and with 
the DPSS 561-10 laser on the Zeiss LSM 510 META confocal microscope. 
To quantify the intensity of the nuclear foci, single-cell images were ac-
quired with no saturated pixels, always using the same settings. The mean 
intensity of ﬂ  uorescence in the nuclear RNA focus was determined using 
ImageJ (http://rsb.info.nih.gov/ij/). Line proﬁ  les were obtained from 
  unprocessed images using the LSM 510 software.
Western blotting
Total cell extracts were prepared as described in Custódio et al. (2006). 
Volumes of total extract equivalent to 10
6 cells were fractionated on a 7% 
polyacrylamide-SDS gel and proteins were transferred to nitrocellulose in 
24 mM Tris, 193 mM glycine, and 20% methanol for 16 h at 30 mA. 
Western blotting with mouse monoclonal against HA epitope (HA.11; 
Covance) and mouse monoclonal against α-tubunin (clone B-5-1-2; Sigma-
Aldrich) was as previously described (Custódio et al., 2006).
S1-nuclease and RNase protection assays
The levels of endogenous murine β
major-globin gene (Hbb1) pre-mRNA were 
analyzed by an S1-nuclease protection assay as described (Custódio et al., 
2006). RNase protection assays were performed as described (McCracken 
et al., 2002; Custódio et al., 2004). HBB RNase protection probes 
(McCracken et al., 1997a) were prepared by in vitro transcription with T7 
RNA polymerase in the presence of α-[
32P]UTP (GE Healthcare). In each 
reaction nuclear RNA, prepared as described (Custódio et al., 2004), was 
incubated with excess of the antisense RNA probe overnight at 50°C, and 
the hybridization products were digested with a mixture of RNase T1 and 
A (Ambion) at 37°C for 1 h. The RNase-protected fragments were resolved 
on a 6% denaturing polyacrylamide gel and the intensity of the bands was 
quantiﬁ  ed using a PhosphorImager (Molecular Dynamics). After quantiﬁ  ca-
tion of each gel band, background was subtracted and the values were nor-
malized for different U residue contents of the protected probe fragments.A NEW ROLE FOR THE CTD IN MRNA BIOGENESIS • CUSTÓDIO ET AL. 207
Poly(A) tail length analysis
The poly(A) tail length analysis of HBB transcripts was performed by PCR 
using the ligase-mediated poly(A) test (LM-PAT) described by Sallés et al. 
(1999). For cDNA synthesis we used 3 μg of total RNA, 50 ng of phos-
phorylated oligo dT12, and 1 μg of oligo(dT)-anchor primer. As a control, 
RNA was deadenylated by digestion with RNase H in the presence of 
oligo dT12–18. For PCR ampliﬁ  cation, 1 μl of the template LM-PAT cDNA 
was added to a standard 25-μl PCR reaction containing 12.5 pmol of 
oligo(dT)-anchor primer and 12.5 pmol of an HBB speciﬁ  c primer that 
hybridizes 254 nt upstream from the polyadenylation signal (5′-G  C  A  A  C  G  T  -
G  C  T  G  G  T  C  T  G  T  G  T  G  C  T  G  -3′). The ampliﬁ  ed products were resolved by 
electrophoresis on a 2% agarose gel stained with ethidium bromide.
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